MedTrace Logo

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

NCT03008187 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2025-04-29

Study results available
· View outcomes & findings →

Summary

The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).

Conditions

Interventions

DRUG

MEN1703

MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Theradex

    collaborator INDUSTRY

  • Menarini Group

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2023-04-13
Completion
2023-04-13
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03008187 on ClinicalTrials.gov